Cargando…

Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunocompetent Orthotopic Murine Model

SIMPLE SUMMARY: Treatment of pancreas ductal adenocarcinoma (PDAC) remains challenging due to the late stage of presentation, limited efficacy of cytotoxic chemotherapies, and aggressive tumor biology. Novel therapeutic targets are desperately needed. The voltage-gated potassium channel, Kv1.3, is o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Weiwei, Wilson, Gregory C., Bachmann, Magdalena, Wang, Jiang, Mattarei, Andrea, Paradisi, Cristina, Edwards, Michael J., Szabo, Ildiko, Gulbins, Erich, Ahmad, Syed A., Patel, Sameer H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179813/ https://www.ncbi.nlm.nih.gov/pubmed/35681598 http://dx.doi.org/10.3390/cancers14112618

Ejemplares similares

Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells
por: Peruzzo, Roberta, et al.
Publicado: (2017)

Voltage-Gated Potassium Channels as Regulators of Cell Death
por: Bachmann, Magdalena, et al.
Publicado: (2020)

Pharmacological targeting of the mitochondrial calcium-dependent potassium channel KCa3.1 triggers cell death and reduces tumor growth and metastasis in vivo
por: Bachmann, Magdalena, et al.
Publicado: (2022)

Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model
por: Severin, Filippo, et al.
Publicado: (2022)

Synergistic effect of Abraxane that combines human IL15 fused with an albumin‐binding domain on murine models of pancreatic ductal adenocarcinoma
por: Hsu, Fei‐Ting, et al.
Publicado: (2022)

Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma
por: Wilson, Gregory C., et al.
Publicado: (2023)

Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System
por: Chen, Yen-Ju, et al.
Publicado: (2020)

Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in vivo
por: Patel, Sameer H., et al.
Publicado: (2023)

A Paclitaxel-Loaded Recombinant Polypeptide Nanoparticle Outperforms Abraxane in Multiple Murine Cancer Models
por: Bhattacharyya, Jayanta, et al.
Publicado: (2015)

Novel Mitochondria-Targeted Furocoumarin Derivatives as Possible Anti-Cancer Agents
por: Mattarei, Andrea, et al.
Publicado: (2018)

Albumin-bound formulation of paclitaxel (Abraxane(®) ABI-007) in the treatment of breast cancer
por: Miele, Evelina, et al.
Publicado: (2009)

Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer
por: Ai, Dan, et al.
Publicado: (2016)

nab-Paclitaxel (Abraxane(®)): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors
por: Iglesias, J
Publicado: (2009)

Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane
por: Feng, Zhongling, et al.
Publicado: (2009)

Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp
por: Zhao, Minzhi, et al.
Publicado: (2015)

Recombinant nanocomposites by the clinical drugs of Abraxane(®) and Herceptin(®) as sequentially dual-targeting therapeutics for breast cancer
por: Ding, Shuang, et al.
Publicado: (2018)

Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models
por: Nolan, Kyle, et al.
Publicado: (2020)

Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family
por: Peruzzo, Roberta, et al.
Publicado: (2020)

Corrigendum to “Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family” [Redox Biol. 37 (2020 Sep 6) 101705–101721]
por: Peruzzo, Roberta, et al.
Publicado: (2021)

Intracellular ion channels and cancer
por: Leanza, Luigi, et al.
Publicado: (2013)

Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats
por: Suzuki, Shugo, et al.
Publicado: (2014)

An Angiopep2-PAPTP Construct Overcomes the Blood-Brain Barrier. New Perspectives against Brain Tumors
por: Parrasia, Sofia, et al.
Publicado: (2021)

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple Myeloma
por: Kadow, Stephanie, et al.
Publicado: (2022)

Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts
por: Vallo, Stefan, et al.
Publicado: (2016)

Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model
por: Xiao, Zhengwen, et al.
Publicado: (2011)

The Tyrosine Kinase p56(lck) Mediates Activation of Swelling-induced Chloride Channels in Lymphocytes
por: Lepple-Wienhues, Albrecht, et al.
Publicado: (1998)

DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin
por: Sun, Xilin, et al.
Publicado: (2016)

Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane™) for peritoneal carcinomatosis – a phase I first-in-human study
por: Van De Sande, Leen, et al.
Publicado: (2018)

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study
por: Drusbosky, Leylah, et al.
Publicado: (2020)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Curcumin–cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer
por: Rocks, N, et al.
Publicado: (2012)

Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells
por: Leanza, Luigi, et al.
Publicado: (2012)

Correction: DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin
por: Sun, Xilin, et al.
Publicado: (2023)

A Plea for More Drastic Control
Publicado: (1921)

Atypical Cutaneous Sporotrichosis in an Immunocompetent Adult: Response to Potassium Iodide
por: Gandhi, Nikita, et al.
Publicado: (2016)

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
por: Dhayat, Sameer A., et al.
Publicado: (2015)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jkeqspocsgkp9lot1hfmrpbbvj